Niravam (alprazolam orally disintegrating tablets), Parcopa (carbidopa-levodopa orally disintegrating tablets) and Kemstro (baclofen orally disintegrating tablets) are central nervous system (CNS) products.
Niravam and Parcopa have been commercially available in the US since 2005 and 2004, respectively. There is one approved generic competitor to Parcopa. Kemstro and Fluxid are both FDA approved but not yet commercially available in the US.
Seamus Mulligan, chairman and CEO of Azur, said: “We are pleased to add these valuable products to our portfolio. In particular, Niravam, Parcopa and Kemstro represent a broadening of our CNS franchise and are consistent with our approach of improving our products through the application of value-added drug delivery technologies.”